Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00118404 |
This study will determine the effectiveness of continuation phase cognitive therapy versus antidepressant medication in preventing relapse of depression in people with recurrent depression.
Condition | Intervention | Phase |
---|---|---|
Depression |
Behavioral: Continuation phase cognitive therapy Drug: Continuation phase fluoxetine Other: Continuation phase pill placebo Behavioral: Initial phase cognitive therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Prophylactic Cognitive Therapy for Depression. |
Enrollment: | 523 |
Study Start Date: | December 1999 |
Estimated Study Completion Date: | May 2012 |
Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Participants will receive initial phase and continuation phase cognitive therapy
|
Behavioral: Continuation phase cognitive therapy
Continuation phase cognitive therapy includes 10 sessions over 8 months.
Behavioral: Initial phase cognitive therapy
For the first 12 weeks, all participants will receive between 16 and 20 cognitive therapy sessions.
|
2: Placebo Comparator
Participants will receive initial phase cognitive therapy and continuation phase pill placebo
|
Other: Continuation phase pill placebo
The dosage of pill placebo will be increased to 40 mg over 8 months.
Behavioral: Initial phase cognitive therapy
For the first 12 weeks, all participants will receive between 16 and 20 cognitive therapy sessions.
|
3: Active Comparator
Participants will receive initial phase cognitive therapy and continuation phase fluoxetine
|
Drug: Continuation phase fluoxetine
The dosage of fluoxetine will be increased to 40 mg over 8 months.
Behavioral: Initial phase cognitive therapy
For the first 12 weeks, all participants will receive between 16 and 20 cognitive therapy sessions.
|
Cognitive therapy (CT) is a short-term talking therapy that focuses on changing negative thinking patterns and helping patients develop coping skills to deal with their experiences. Evidence suggests that CT is effective in treating a number of psychiatric conditions, including anxiety and anger. This study will determine the effectiveness of cognitive therapy versus antidepressant medication or placebo in preventing relapse of depression in people with recurrent depression.
This study will last approximately 36 months and will comprise three phases. For the first 12 weeks, all participants will receive between 16 and 20 CT sessions. Participants will then be randomly assigned to receive additional CT sessions, antidepressants, or placebo for an additional 8 months. Upon completing treatment, participants will have follow-up study visits once every 4 months for the next 24 months. Clinician-rated scales and questionnaires will be used to assess depressive symptoms of participants at study start and at the end of each study phase.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
University of Pittsburgh Medical Center Western Psychiatric Institute and Clinic | |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Texas | |
University of Texas Southwestern Medical Center at Dallas | |
Dallas, Texas, United States, 75390 |
Principal Investigator: | Robin B. Jarrett, PhD | University of Texas Southwestern Medical Center at Dallas |
Responsible Party: | The University of Texas Southwestern Medical Center at Dallas ( Robin B. Jarrett, PhD, Professor of Psychiatry ) |
Study ID Numbers: | R01 MH58397, R01 MH69619, DSIR 83-ATP |
Study First Received: | July 6, 2005 |
Last Updated: | October 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00118404 History of Changes |
Health Authority: | United States: Federal Government |
Cognitive therapy Antidepressants Psychotherapy Counseling |
Neurotransmitter Agents Depression Psychotropic Drugs Depressive Disorder Serotonin Uptake Inhibitors Recurrence Serotonin |
Behavioral Symptoms Fluoxetine Mental Disorders Mood Disorders Antidepressive Agents, Second-Generation Antidepressive Agents |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Depression Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Depressive Disorder Serotonin Uptake Inhibitors Pharmacologic Actions |
Behavioral Symptoms Fluoxetine Serotonin Agents Mental Disorders Therapeutic Uses Mood Disorders Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |